Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?
- 30 November 2011
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 37 (7), 533-542
- https://doi.org/10.1016/j.ctrv.2010.11.004
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerDrug Resistance Updates, 2009
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Mutations of the BRAF gene in human cancerNature, 2002